Creative Planning’s Standard BioTools LAB Stock Holding History

Creative Planning’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17K	Sell	18,468 -27,567	-60%	-$33.4K	﹤0.01%	4052
2025 Q4	$58.9K	Sell	46,035 -16,961	-27%	-$22.8K	﹤0.01%	3789
2025 Q3	$81.9K	Buy	62,996 +1,894	+3%	+$2.48K	﹤0.01%	3703
2025 Q2	$73.3K	Buy	61,102 +22,082	+57%	+$24.5K	﹤0.01%	3473
2025 Q1	$42.1K	Sell	39,020 -8,258	-17%	-$11.6K	﹤0.01%	3358
2024 Q4	$82.7K	Buy	47,278 +26,950	+133%	+$50.2K	﹤0.01%	3180
2024 Q3	$39.2K	Buy	+20,328	New	+$39.8K	﹤0.01%	3113
2015 Q4	–	Sell	-5,000	Closed	-$41K	–	4502
2015 Q3	$41K	Buy	+5,000	New	+$78.7K	﹤0.01%	2175

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Creative Planning's LAB Position: Q1 2026 in Review

Creative Planning reduced its Standard BioTools (LAB) stake by 60% in Q1 2026, selling an estimated $33.4K and leaving 18,468 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #4052.

Creative Planning first reported a position in LAB in Q3 2015 and has held it in 8 quarters since. The position peaked at $82.7K in Q4 2024. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

Creative Planning held 18,468 shares of Standard BioTools worth $17K as of Q1 2026.
Creative Planning sold 27,567 Standard BioTools shares in Q1 2026, an estimated $33.4K.
Standard BioTools made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #4052 holding.
Creative Planning first reported a position in Standard BioTools in Q3 2015 and has held it in 8 quarters since.
Creative Planning's Standard BioTools position peaked at $82.7K in Q4 2024.
155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.